Form 8-K - Current report:
SEC Accession No. 0000950170-22-023836
Filing Date
2022-11-09
Accepted
2022-11-09 16:07:53
Documents
14
Period of Report
2022-11-09
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K evok-20221109.htm   iXBRL 8-K 58596
2 EX-99.1 evok-ex99_1.htm EX-99.1 57665
3 GRAPHIC img208171256_0.jpg GRAPHIC 5594
  Complete submission text file 0000950170-22-023836.txt   246650

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT evok-20221109.xsd EX-101.SCH 2478
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT evok-20221109_lab.xml EX-101.LAB 12806
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT evok-20221109_pre.xml EX-101.PRE 9459
8 EXTRACTED XBRL INSTANCE DOCUMENT evok-20221109_htm.xml XML 4534
Mailing Address 420 STEVENS AVENUE SUITE 370 SOLANA BEACH CA 92075
Business Address 420 STEVENS AVENUE SUITE 370 SOLANA BEACH CA 92075 858-345-1494
Evoke Pharma Inc (Filer) CIK: 0001403708 (see all company filings)

EIN.: 208447886 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36075 | Film No.: 221372588
SIC: 2834 Pharmaceutical Preparations